Savvy Advisors Inc. Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Savvy Advisors Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 86.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,851 shares of the company's stock after acquiring an additional 7,837 shares during the quarter. Savvy Advisors Inc.'s holdings in Johnson & Johnson were worth $2,437,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at about $32,000. Finally, Conquis Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Barclays increased their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research report on Tuesday, January 28th. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Bank of America reduced their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.50.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $0.71 during midday trading on Tuesday, reaching $153.66. 10,723,823 shares of the stock were exchanged, compared to its average volume of 7,973,461. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a 50-day simple moving average of $159.39 and a two-hundred day simple moving average of $155.10. The firm has a market cap of $370.29 billion, a price-to-earnings ratio of 23.11, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.